ClinicalTrials.gg
RecruitingNCT07501429Updated Oct 22, 2026

Shockwave for Elbow and Wrist Spasticity in People With Spinal Cord Injury

A Phase 1 interventional study of Focused extracorporeal shockwave therapy in Spinal Cord Injury, Spasticity and Shockwave Therapy, sponsored by Kessler Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Kessler Foundation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Spinal Cord Injuries by Kessler Foundation — 22 open to participants now, 22 under way, none of them phase 3. Spinal Cord Injuries · Kessler Foundation.

Planned enrollment
31st of 38
12 · median 26
Started
2026
with 3 others
Phase 1
5 of 41
2 open now
Primary completion
2028-09
later than 15 of 21 live
Registered
37th of 41
by date

Among the 41 studies in Spinal Cord Injuries by Kessler Foundation, this one is the 31st largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 15 of the 21 other live ones, and was the 37th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

22 of the 41 studies in Spinal Cord Injuries by Kessler Foundation are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Spinal Cord Injuries by Kessler Foundation, or all of them as a file.
02

Study summary

Approximately 305,000 people live with a spinal cord injury (SCI) in the United States. Sixty percent of these individuals have tetraplegia, which can cause significant dysfunction of the arms and hands. One of the consequences of SCI is spasticity - involuntary activation of muscles that can hinder bodily functions and negatively affect participation in various aspects of life. Spasticity can lead to loss of functional independence and activity limitations, cause pain, and lead to mood disorders like depression. It can even interfere with rehabilitation and lead to hospitalization. In people with tetraplegia, spasticity of the arms and hands can have a tremendous impact on independence and quality of life, and thus regaining function in these areas remains a top priority. Unfortunately, spasticity is difficult to treat. Common treatments include physical therapy, including exercise or stretching; medications such as Baclofen; and injections with agents like botulinum toxin (also known as Botox). Botox injections are often implemented alongside other modalities like therapy, yet they are invasive, tend to last for only a few months, and carry potential side effects. One potential non-invasive treatment for upper limb spasticity is focused extracorporeal shockwave therapy (f-ESWT), which involves an external application of high-pressure sound waves, similar to ultrasound. An applicator/handpiece is placed on the skin over the spastic muscle and the focused sound waves are applied. f-ESWT carries no long-term side effects with minimal discomfort during application. However, there has been limited research on this treatment option in people with SCI who have arm and hand dysfunction caused by spasticity. The purpose of this study is to fill in that knowledge gap. This will be accomplished by measuring different aspects of spasticity from the perspective of both the clinician and the person with SCI. These will include clinical measures, such as elbow and wrist range of motion, as well as how the treatment impacts the person's functional independence and quality of life. Ultrasound methods will be used to look at the person's muscles to see if any beneficial changes occur in their structure and stiffness. People with SCI who meet eligibility criteria will be invited to the laboratory to receive f-ESWT, which will occur once per week for three consecutive weeks. Treatment will entail application of f-ESWT to the elbow and wrist flexor muscles. Participants will be invited back to the laboratory to have their spasticity measured by a clinician, be asked questions about how their spasticity has impacted their lives, and have their muscles imaged with ultrasound. Findings from this study are expected to generate insight on whether f-ESWT could be a viable treatment option for spasticity of the arms and hands in people with SCI, and if a larger clinical trial is warranted.

03

Conditions studied

  • Spinal Cord Injury
  • Spasticity
  • Shockwave Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older.
  2. Have chronic, non-progressive SCI of all levels and severities that occurred greater than 1 year prior to their enrollment.
  3. MAS score of between 1+ and 3 in elbow and wrist flexors of the treated upper limb.
  4. Can be treated with shockwaves. include current or recent (within the past 3 months) infection at the site of treatment and severe coagulopathies (e.g. hemophilia).129
  5. No change in antispasmodic medications within the past three months or intended changes over the course of the trial.
  6. Participant is able and willing to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History of surgical procedures in the upper extremity
  2. Severe, inflammatory arthritic diseases
  3. Thrombosis
  4. Anticoagulant medication;
  5. Pregnancy
  6. Cancer
  7. Recent history of local injection of botulinum toxin within 6 months, or phenol/alcohol within the 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Treatment

    Elbow and Wrist Flexor Focused Extracorporeal Shockwave Therapy

    Device: Focused extracorporeal shockwave therapy

Interventions

  • DeviceFocused extracorporeal shockwave therapy

    Three sessions of focused extracorporeal shockwave therapy, applied to forearm and elbow flexor muscles.

06

What researchers measure

Primary outcomes

  1. Change in Modified Ashworth Scale scores

    The Modified Ashworth Scale (MAS) is a physical exam maneuver used frequently both clinically and for research purposes to assess the increase in velocity-dependent muscle tone after neurologic disorders. We will be focusing on the MAS score of the ankle plantar flexors. This measure is included in the NINDS list of CDE recommendations for SCI. Specifically, it evaluates the resistance to passive stretch of the ankle joint through full range of motion. Scores range from 0 (no spasticity) to 4 (severe spasticity).

    Time frame: 4 weeks

Secondary outcomes

  1. Change in Modified Ashworth Scale scores

    The Modified Ashworth Scale (MAS) is a physical exam maneuver used frequently both clinically and for research purposes to assess the increase in velocity-dependent muscle tone after neurologic disorders. We will be focusing on the MAS score of the ankle plantar flexors. This measure is included in the NINDS list of CDE recommendations for SCI. Specifically, it evaluates the resistance to passive stretch of the ankle joint through full range of motion. Scores range from 0 (no spasticity) to 4 (severe spasticity).

    Time frame: 8 weeks

  2. Change in Modified Penn Spasticity Frequency Scale

    The Modified Penn Spasticity Frequency Scale (mPSFS) is a self-report scale with two components, which is meant to provide a more complete understanding of an individual's spasticity status. The first component is comprised of a five-point scale, which assesses spasm frequency between 0 ("no spasms") and 4 ("spontaneous spasms occurring more than 10 times per hour"). The second component includes a three-point scale, which assesses spasm severity between 1 ("mild") and 3 ("severe"); this component is not answered if the individual reports no spasms in part one.

    Time frame: 4 weeks

  3. Change in Modified Penn Spasticity Frequency Scale

    The Modified Penn Spasticity Frequency Scale (mPSFS) is a self-report scale with two components, which is meant to provide a more complete understanding of an individual's spasticity status. The first component is comprised of a five-point scale, which assesses spasm frequency between 0 ("no spasms") and 4 ("spontaneous spasms occurring more than 10 times per hour"). The second component includes a three-point scale, which assesses spasm severity between 1 ("mild") and 3 ("severe"); this component is not answered if the individual reports no spasms in part one.

    Time frame: 8 weeks

  4. Change in Modified Patient-Reported Impact of Spasticity Measure

    The Modified Patient-Reported Impact of Spasticity Measure (mPRISM) is a self-reported instrument with 37 items to quantify the impact of spasticity on physical, psychological, and social health-related QOL domains. Each item is rated using a scale of 0 ("never") to 3 ("often/very often"). The scale's psychometric properties have been well-established, including floor and ceiling effects for the various subscales, and it has been shown to be both valid and reliable.

    Time frame: 4 weeks

  5. Change in Modified Patient-Reported Impact of Spasticity Measure

    The Modified Patient-Reported Impact of Spasticity Measure (mPRISM) is a self-reported instrument with 37 items to quantify the impact of spasticity on physical, psychological, and social health-related QOL domains. Each item is rated using a scale of 0 ("never") to 3 ("often/very often"). The scale's psychometric properties have been well-established, including floor and ceiling effects for the various subscales, and it has been shown to be both valid and reliable.

    Time frame: 8 weeks

  6. Participant Global Impression of Change

    The Participant Global Impression of Change (PGIC) measures global treatment effect by asking the participant to rate with a 7-point scale (anchored by 1 \["very much worse"\] and 7 \["very much improved"\]) their overall impression following treatment as compared to prior. This scale provides an indication of clinically important improvement and has been used to assess efficacy of spasticity treatments in SCI. 11-week scores will be considered a primary outcome.

    Time frame: 4 weeks

  7. Participant Global Impression of Change

    The Participant Global Impression of Change (PGIC) measures global treatment effect by asking the participant to rate with a 7-point scale (anchored by 1 \["very much worse"\] and \["very much improved"\]) their overall impression following treatment as compared to prior. This scale provides an indication of clinically important improvement and has been used to assess efficacy of spasticity treatments in SCI. 11-week scores will be considered a primary outcome.

    Time frame: 8 weeks

  8. Biceps brachii muscle echogenicity

    Echogenicity is a measure of a tissue's "brightness." In muscle, this reflects the concentration of connective tissue and thus is a marker of muscle health. We will apply quantitative ultrasound image collection and analysis techniques to quantify the average echogenicity of biceps muscle in longitudinal view.

    Time frame: 4 weeks

  9. Biceps brachii muscle echogenicity

    Echogenicity is a measure of a tissue's "brightness." In muscle, this reflects the concentration of connective tissue and thus is a marker of muscle health. We will apply quantitative ultrasound image collection and analysis techniques to quantify the average echogenicity of biceps muscle in longitudinal view.

    Time frame: 8 weeks

  10. Biceps brachii muscle elasticity

    Elasticity is a measure of a tissue's stiffness. Muscles that are more spastic and have a greater concentration of connective tissue appear stiffer than those in better health. We will apply quantitative ultrasound image collection and analysis techniques to quantify the average elasticity of biceps muscle in longitudinal view.

    Time frame: 4 weeks

  11. Biceps brachii muscle elasticity

    Elasticity is a measure of a tissue's stiffness. Muscles that are more spastic and have a greater concentration of connective tissue appear stiffer than those in better health. We will apply quantitative ultrasound image collection and analysis techniques to quantify the average elasticity of biceps muscle in longitudinal view.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared to protect participants' private clinical data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2028, 30 months after the start.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Mar 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 30, 2026
StartActual
Mar 6, 2026was Apr 2026
Primary completionEst.
Sep 2028
CompletionEst.
Dec 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Mar 6, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Apr 2026→Mar 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07501429
Lead sponsor
Kessler Foundation
Responsible party
Nathan Hogaboom, PhD (Research Scientist, Kessler Foundation) — Principal investigator
First posted
Mar 30, 2026
Start date
Mar 6, 2026
Primary completion
Sep 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Shalaka Paranjpe, MS
Contact
sparanjpe@kesslerfoundation.org
973-327-3572
Nathan Hogaboom, PhD
Contact
nhogaboom@kesserfoundation.org
973-324-3584

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion